Síndrome general y dolores óseos en un paciente tratado con tenofovir

Síndrome general y dolores óseos en un paciente tratado con tenofovir

El tenofovir (TDF), es el único inhibidor de la transcriptasa inversa análogo nucleótido para el tratamiento de la infección por virus de la inmunodeficiencia humana (VIH). Ocasionalmente, puede producir insuficiencia renal aguda y síndrome de Fanconi. Presentamos el caso de un varón de 64 años c...

Full description

Bibliographic Details
Main Authors:	Arnaiz de las Revillas F, Marcote Ibáñez C, González-Lamuño D, García Unzueta M, Lino Montenegro E, Riancho JA
Format:	Article
Language:	English
Published:	Ibáñez & Plaza Asoc. 2015-11-01
Series:	Revista de Osteoporosis y Metabolismo Mineral
Subjects:	síndrome general tenofovir osteomalacia
Online Access:	http://revistadeosteoporosisymetabolismomineral.com/2017/07/11/sindrome-general-y-dolores-oseos-en-un-paciente-tratado-con-tenofovir/

Similar Items

Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use
by: Mana Rao, et al.
Published: (2021-05-01)

Bilateral atraumatic neck of femur fractures secondary to tenofovir-induced fanconi syndrome
by: Vikaesh Moorthy, et al.
Published: (2023-01-01)

A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B
by: Dongwoo Kim, et al.
Published: (2016-12-01)

Osteomalacia y Síndrome de Sjögren primario
by: José Martínez Pérez, et al.
Published: (2022-04-01)

Aging, human immunodeficiency virus, and bone health
by: Kim C Mansky
Published: (2010-09-01)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
by: Hung-Yao Lin, et al.
Published: (2022-04-01)

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
by: Pei-Yuan Su, et al.
Published: (2021-11-01)

An overview of tenofovir and renal disease for the HIV-treating clinician
by: Willem D.F. Venter, et al.
Published: (2018-07-01)

Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024-02-01)

Tenofovir-associated kidney disease in Africans: a systematic review
by: Takudzwa J. Mtisi, et al.
Published: (2019-06-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Tenofovir-induced Leukocytoclastic Vasculitis
by: Said A. Al-Busafi, et al.
Published: (2017-09-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Tenofovir-induced quadriparesis
by: Ashalatha Muppur, et al.
Published: (2020-01-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
by: Hyeyeon Hong, et al.
Published: (2024-04-01)

Tenofovir in the Management of Chronic Hepatitis B Infection During Pregnancy
by: Yeşim Çekin, et al.
Published: (2012-06-01)

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
by: Hyeyeon Hong, et al.
Published: (2024-01-01)

Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV
by: Michał Łomiak, et al.
Published: (2023-09-01)

Efficacy and safety of Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B with High Baseline Viral Load
by: Ahmed Gad Mohamed Ahmed*, et al.
Published: (2020-07-01)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
by: Jared M. Gilbert, et al.
Published: (2022-11-01)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
by: Chan Ho Park, et al.
Published: (2016-03-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
by: Fa- Da Wang, et al.
Published: (2023-09-01)

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV‐Infected Patients
by: Ruijun Chen, et al.
Published: (2017-04-01)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
by: Zekun Liu, et al.
Published: (2023-11-01)

Case of Pregnant Hepatitis B Presenting with Hepatic Exacerbation After Cessation of Tenofovir Treatment
by: Yeliz ÖZEN
Published: (2017-12-01)

Associations between plasma tenofovir concentration and renal function markers in HIV-infected women
by: Mwila Mulubwa, et al.
Published: (2016-07-01)

[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
by: Fabio Tarsetti, et al.
Published: (2015-12-01)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
by: Kensuke Abe, et al.
Published: (2024-02-01)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
by: Abul H Manik, et al.
Published: (2021-01-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
by: Eric H. Decloedt, et al.
Published: (2021-04-01)

Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection
by: Bengü TATAR, et al.
Published: (2020-05-01)

Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy
by: I-Cheng Lee, et al.
Published: (2022-09-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)